Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

41 results about "Nausea vomiting" patented technology

Modified release compositions of milnacipran

A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax at 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng / ml, preferably below 2000 ng / ml, and most preferably below 1000 ng / ml. The composition allows milnacipran to be delivered over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.
Owner:COLLEGIUM PHARMA INC

Pulsatile release compositions of milnacipran

InactiveUS20060003004A1Minimize exposureReduces milnacipran gastrointestinal side effectCapsule deliveryCoatingsPalpitationsPanic
A once-a-day oral milnacipran pulsatile release composition has been developed that releases the drug in spaced apart “pulses”. The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. This dosage form provides in vivo drug plasma levels characterized by Cmax below 3000 ng / ml, preferably below 2000 ng / ml, and most preferably below 1000 ng / ml. The composition provides pulsatile release of milnacipran to produce a therapeutic effect over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.
Owner:COLLEGIUM PHARMA INC

Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse

InactiveUS20100144645A1Lower potentialAmenable to synthesizing conjugatesBiocideNervous disorderChemical MoietyOpioid antagonist
The invention generally relates to compositions and methods with covalently bound compounds, such as controlled substances covalently attached to a chemical moiety, and opioid antagonists or covalently bound opioid antagonists to enhance analgesic potency and/or attenuate one or more adverse effects of covalently bound compounds, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence), physical dependence or pruritis. This invention relates to compositions and methods for selectively enhancing the analgesic potency of a covalently bound compound and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of a covalently bound compound. The methods of the invention comprise administering to a subject an analgesic or sub-analgesic amount of a covalently bound compound and an amount of excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of a covalently bound compound and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of covalently bound compound. The invention also relates to the addition of covalently-bound opioid antagonists to the compositions containing covalently bound compounds such that if the compositions are subjected to manipulation by illicit chemists, the opioid antagonist is released effectively reducing or eliminating the euphoric effect of the covalently bound compounds.
Owner:SHIRE PLC

Galenical preparations of dapsone and related sulphones, and method of therapeutic and preventative treatment of disease

Dapsone and related sulfones are known to have therapeutic activity against leprosy, dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposiís sarcoma, pneumocystis carinií (pneumonia), subcorneal pustular dermatosis and cystic acne, in patients in need of such therapy. These sulfones are also known to have therapeutic activity against memory loss in patients in need of such therapy, including patients suffering from Alzheimer's disease and related neurodegenerative disorders. It has now been found that new, modified-release formulations of dapsone and related sulfones may also be used that decrease side effects and increase effectiveness of the drugs. New methods are disclosed utilizing certain formulations of dapsone and related sulfones that improve the therapeutic index of said drugs. Side effects of these drugs are known to those skilled in the art and include, but are not restricted to anorexia, psychosis, agranulocytosis, peripheral neuritis, hemolysis, methemoglobinemia, nausea, vomiting, headache, dizziness, tachycardia, nervousness, insomnia and skin disorders. Modified-release (as defined herein) formulations of dapsone have now been found to avoid some or all of these side effects, and to have more efficacy on potency.
Owner:IMMUNE NETWORK

Chinese medicinal preparation for treating pernicious vomiting

The invention relates to the technical field of Chinese medicines, in particular to a pure Chinese medicinal preparation for treating pernicious vomiting. The pure Chinese medicinal preparation is prepared from the following Chinese herbal medicines in parts by weight: 10 to 30 parts of codonopsis pilosula, 10 to 30 parts of large-head atractylodes rhizome, 10 to 30 parts of poria, 10 to 30 parts of south dodder seed, 8 to 20 parts of pinellia tuber, 10 to 30 parts of dried orange peel, 10 to 30 parts of wrinkled gianthyssop herb, 15 to 35 parts of red ochre, 8 to 20 parts of costus root, 10 to 30 parts of bitter orange, 8 to 20 parts of amomum fruit, 10 to 30 parts of perilla, 10 to 30 parts of bamboo shavings and 5 to 10 parts of liquorice root; the pure Chinese medicinal preparation can be prepared into pharmaceutically acceptable medicines such as pills, powder, decoction and the like; the pure Chinese medicinal preparation is prepared from pure Chinese medicines, and can tonify the spleen, soothe the liver, promote the circulation of qi, harmonize the stomach, lower adverse qi, control nausea and vomiting, tonify the kidney and prevent miscarriage; the pure Chinese medicinal preparation is suitable for symptoms of early trimester of pregnancy, nausea vomiting, non-eating, vomiting immediately after ingestion, acid water or bitter water vomiting, dislike of smelling greasy food, tastelessness, drool vomiting, dizziness, fatigue of a body, flatulence, thoracic fullness, hypochondriac pain and the like; and the Chinese medicinal preparation is small in dosage, good in curative effect, quick in response and obvious in pharmacological effect, and does not have toxic or side effects.
Owner:赵自强

Micro-powder dom peridone maleate medicinal composition and its preparing method

The present invention relates to a medicine composition with domperidone maleate. It is characterized by that said medicine composition is micropowdered, and can be used for invigorating function of gastrointestinal tract and curing the diseases of dyspepsia and nausea-vomiting, etc. Said micropowdered domperidone maleate preparation can raise its bioavailability. Besides, said invention also provides its preparation method.
Owner:NANJING CHANGAO PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products